GT Biopharma Inc expected to post a loss of 31  cents a share - Earnings Preview

GT Biopharma

13/05/2022 21:06

* GT Biopharma Inc  GTBP.OQ   GTBP.O  is expected to show no
change in quarterly revenue when it reports  results on May 16
(estimated). 
    * ​Refinitiv's mean analyst estimate for GT Biopharma Inc is
for a
loss of 31 cents per share. For the same quarter last year, the
company reported a loss of $1.83 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $18​, above​ its last closing price of $1.80. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.20       -0.21      -0.52     Missed  -151.6
 Sep. 30 2021  -0.15       -0.21      -0.19     Beat    9.5
 Jun. 30 2021  -0.26       -0.28      -0.13     Beat    53​
 Mar. 31 2021  -0.25       -0.24      -1.83     Missed  -646.9
 ​​Dec.        -0.04       -0.04      -3.39     Missed  -7,433
 31 2020                                                .3
                                                        ​
 This summary was machine generated May 13 at 20:06 GMT.  All
figures in US dollars  unless otherwise stated